Jeffrey Wolf, MD, on Next-Generation CAR T Cell Therapy and the Future of Multiple Myeloma Treatments

Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.

Jeffrey Wolf, MD, of the University of California San Francisco, discussed the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma in an interview with CancerNetwork.

Transcription:

This year, I’m seeing the results with T-cell engagers (TCE) and believing that, although we’re probably not curing anyone, we’re getting at least as good results as we are with CAR Ts, so maybe we’ve leapfrogged with TCEs beyond CAR Ts. But I’m looking forward, in the next few years, to next-generation CAR Ts, maybe dual CARs that will attack more than 1 target. And that will probably leapfrog the TCEs. So, I think ultimately, we’re going to be looking at either drugs or cells that are going to give us 3-4 years of control or cure. And I really think that we’re probably 5 years away from truly curing some of our patients.

Related Videos
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
Noa Biran, MD, an expert on multiple myeloma
Experts on multiple myeloma
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
Experts on multiple myeloma
Experts on multiple myeloma
Related Content